ERC Starting Grant · 2025
Approximately 1 in 5 newly diagnosed cancers is a second or subsequent cancer related to treatment for a first cancer. Second breast cancers (SBCs) are the most commonly diagnosed. Those who develop SBCs have reduced treatment options and worse outcomes than comparable individuals with first primary breast cancers. There are over 12 million female cancer survivors in the EU, of whom at least 15% will develop an SBC. A better understanding of the etiology and risk factors for SBC is therefore essential. There is an intriguing and poorly understood negative association between systemic autoimmune diseases and breast cancer, repeatedly documented in distinct populations. My preliminary data…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.